HOPITAUX UNIVERSITAIRES DE STRASBOURG

Their core work

Hôpitaux Universitaires de Strasbourg is one of France's major university hospital systems, combining clinical care with translational research. In H2020, they contribute clinical expertise in rare diseases, autoimmune disorders (particularly Sjögren's syndrome), and kidney transplantation immunology. Their role centers on providing patient cohorts, clinical trial infrastructure, and immunological monitoring capabilities to large European research consortia.

What they specialise in

How they've shifted over time

All four projects fall within 2019–2021, so the timeline is compressed. Early participation (2019) focused on rare disease data infrastructure, FAIR principles, and autoimmune disease stratification through clinical trials. By 2021, the focus shifted toward transplant immunology, viral biomarker monitoring, and supporting European-level rare disease research networks — suggesting a move from data-sharing frameworks toward more applied clinical immunology.

Moving toward personalized immunosuppression and viral biomarker-guided clinical decisions, suggesting growing strength in precision medicine for transplantation.

How they like to work

Strasbourg University Hospital participates exclusively as a partner — never as coordinator in these projects — which is typical for hospital-based clinical sites contributing patient data and trial infrastructure rather than leading project management. They join large consortia (189 unique partners across 36 countries), indicating they are a trusted clinical node in major European networks. Their value to consortia lies in clinical access and patient cohorts, not in project leadership.

Connected to 189 unique partners across 36 countries, reflecting involvement in very large European health research consortia. Their network is broad rather than deep, consistent with multi-site clinical trial participation spanning most of Europe and beyond.

What sets them apart

As a major French university hospital, they offer something many research institutes cannot: direct access to patient populations for clinical trials in rare diseases, autoimmune conditions, and transplantation. Their combination of rare disease expertise and transplant immunology is uncommon — few clinical partners can contribute meaningfully to both areas. For consortium builders, they bring clinical trial infrastructure in eastern France with strong links to the broader European rare disease community.

Highlights from their portfolio

• NECESSITY
  Largest funding share (EUR 337,733) — a complex multi-arm clinical trial for Sjögren's syndrome, an underserved autoimmune condition with few validated endpoints.
• TTV GUIDE TX
  Innovative use of Torque Teno Virus as a biomarker for personalizing immunosuppression after kidney transplant — a Phase II randomized clinical trial with direct patient impact.